Zhu Wenchen, the first richest man in Henan, was investigated by the China Securities Regulatory Commission for suspected information disclosure and violations of laws and regulations.According to Zhu Wenchen's actual controlled pharmaceutical stocks*ST Furen, it was announced on the evening of Monday (May 22), and the Shanghai Stock Exchange decided to terminate the company's stock listing.
According to each network report,*ST Furen (formerly referred to as Fu Ren Pharmaceutical) issued an announcement that night that the company received the shares of the Shanghai Stock Exchange on May 22The decision to terminate the listing, the Shanghai Stock Exchange decided to terminate the company's stock listing.
Reporting pointed out that*ST Furen is the first delisting pharmaceutical stock in the A -share market in 2023. According to the delisting adjustment period from May 30 to June 19th, it is currently only four weeks away from its delisting.It's time.
Reported that Fu Ren Pharmaceutical issued an announcement on May 10th that Zhu Wenchen, the company's actual controller and the "richest man in Henan" many times, was in violation of the law.On the 3rd, the CSRC was filed by the China Securities Regulatory Commission.But as of the announcement date, the Inspection Corps has not contacted Zhu Wenchen.
In May 2006, the "Fu Ren Pharmaceutical" pharmaceutical company landed on A shares, and then achieved profitability for 14 consecutive years.The largest M & A case in the market.However, this listed company that spans the two gold industries across the medicine and wine industry. 17 years after landing in A shares, they received the regulatory departments' delisting ultimatum.
According to the announcement issued by*ST Fu Ren on April 28, the advance notice of the listing of the shares of the Pharmaceutical Co., Ltd. issued by the Shanghai Stock Exchange shows that the company's 2022 audited in 2022At the end of the period, net assets were negative, and the 2022 financial accounting report was issued an audit report that could not be expressed.This is the last straw of the company's termination of listing conditions.
The*ST Auxu Ren annual report disclosed until April 28 showed that the company's revenue last year was about 1.469 billion yuan (RMB, the same below, about S $ 280 million), a year -on -year decrease of 2.9%, The loss narrowed by 12.20%year -on -year, but the absolute amount still exceeded 2.8 billion yuan.At the same time, as of the company's net assets decreased by 351.11%year -on -year to 2.09 billion yuan, it has been seriously funded.
*ST Fu Ren said that due to funding difficulties, some business of the company declined.The company integrates the current operating team, and the personnel and departments with ordinary operating efficiency are made to make streamlined adjustments.At the same time, strengthen the control of the company's cost, reduce the expenditure of the necessary expenses, and reduce the expenditure of non -necessary expenses.
For major uncertainty related to continuous operation,*ST Furen said that liquidity difficulties occur in 2022, facing debt overdue, and external guarantee for the pressure on foreign guarantees.The lawsuit, some bank accounts and assets are frozen, and there are major uncertainty in continuous operating capabilities.
Data show that Zhu Wenchen created Auxi Pharmaceutical in 1995, and used 10 years to use Auxi Pharmaceutical as the mother. Through production and operation and capital operation, the company quickly developed into Pharmaceuticals into Pharmaceutical Industry.He is a comprehensive group with the wine industry as the leading industry.In May 2006, Furen Pharmaceutical's backdoor ST Minfeng was listed and became the largest pharmaceutical company in Henan Province.
After the listing of Furen Pharmaceutical, the stock price continued to rise, and Zhu Wenchen's value also rose, and he reached Henan down payment many times.In 2012, Zhu Wenchen won the richest man in Henan for the first time with a net worth of 7.6 billion yuan.In 2013, he won the richest man in Henan in 2013.At the beginning of 2018, Zhu Wenchen once again became the "richest man in Henan" and ranked among the Hu Run wealth list.
However, in 2019, Fu Ren Pharmaceutical's "explosion", the 1.8 billion cash on the account disappeared, the company's available funds were only more than 377,000, and this incident also attracted the attention of supervision.After the investigation, it was found that there were many illegal acts such as false records, major omissions, illegal guarantees, and illegal reduction of holdings.Zhu Wenchen was taken in a 10 -year securities market forbidden measures, and the company and relevant responsible persons were punished.
Public information shows that Zhu Wenchen currently involves 693 restrictions on consumption orders, and has been listed as the executive person of historical dishonesty and the total amount of over 2 billion yuan.
